Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 68

Results For "TN"

2856 News Found

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
News | August 17, 2025

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase


Cohance Lifesciences reports 13% revenue growth in Q1 FY26
News | August 16, 2025

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site


Brightmark and Lewis Salvage recycle over 1 million pounds of medical plastics
News | August 16, 2025

Brightmark and Lewis Salvage recycle over 1 million pounds of medical plastics

Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities


Eight Roads Ventures to host fourth edition of Scale-Up Health conference on Sept 10
News | August 14, 2025

Eight Roads Ventures to host fourth edition of Scale-Up Health conference on Sept 10

The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery


Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags
Drug Approval | August 12, 2025

Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp


Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
News | August 12, 2025

Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad

This strategic investment strengthens Cohance's integrated oligonucleotide platform


LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
People | August 11, 2025

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives


Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
News | August 10, 2025

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore


Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr
News | August 09, 2025

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25